Overview

Celecoxib in Preventing Lung Cancer in Former Heavy Smokers

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing the development or recurrence of lung cancer in former heavy smokers. PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing the development or recurrence of lung cancer in former heavy smokers who are at risk of developing cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Los Angeles
Collaborator:
National Cancer Institute (NCI)
Treatments:
Celecoxib